Clinical Trial: A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07065240) titled 'A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)' on July 03.

Brief Summary: This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

Study Start Date: July 14

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder (MDD) Major Depressive Disorder With Anxious Distress

Intervention: DRUG: SPT-300

A prodrug of allopregnan...